Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic

  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pliant Therapeutics Inc (NQ: PLRX )

13.53 +0.19 (+1.42%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Pliant Therapeutics Inc

< Previous 1 2 3 4 Next >
PLRX Stock Earnings: Pliant Therapeutics Misses EPS for Q2 2024
PLRX stock results show that Pliant Therapeutics missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
7 Biotech Stocks to Buy on the Dip: June 2024
With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation. 
Via InvestorPlace
Pliant Therapeutics' Drug Trial Shows Promise In Reversing Lung Fibrosis In Patients
Phase 2a trial results of Pliant Therapeutics' bexotegrast (PLN-74809) for idiopathic pulmonary fibrosis. Reduced lung collagen, improved FVC, and cough severity, signaling potential fibrosis... 
Via Benzinga
These Analysts Revise Their Forecasts On Pliant Therapeutics Following Q1 Earnings
Via Benzinga
PLRX Stock Earnings: Pliant Therapeutics Misses EPS for Q1 2024
PLRX stock results show that Pliant Therapeutics missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Why Is Liver Disease-Focused Pliant Therapeutics Stock Trading Lower Today?
Pliant Therapeutics reports 12-week interim data for bexotegrast in INTEGRIS-PSC Phase 2a trial. 320 mg group met primary and secondary endpoints, showing well-tolerance and reduction in liver... 
Via Benzinga
The Latest Analyst Ratings for Pliant Therapeutics
Via Benzinga
Where Pliant Therapeutics Stands With Analysts
Via Benzinga
Expert Ratings for Pliant Therapeutics
Via Benzinga
Why Air Products and Chemicals Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Air Products and Chemicals, Inc. (NYSE: APD) fell sharply during Monday’s session after the company reported worse-than-expected first-quarter financial results and lowered FY24 adjusted EPS... 
Via Benzinga
HC Wainwright & Co. Maintains Buy Rating for Pliant Therapeutics: Here's What You Need To Know
Via Benzinga
Johnson Controls International To Rally Over 27%? Here Are 10 Other Analyst Forecasts For Wednesday
Keybanc cut the price target for Danaher Corporation (NYSE: DHR) from $325 to $300. Keybanc analyst Paul Knight maintained an Overweight rating. Danaher shares rose 0.6% to $248.75 in pre-market... 
Via Benzinga
Where Pliant Therapeutics Stands With Analysts
Via Benzinga
Expert Ratings for Pliant Therapeutics
Via Benzinga
Recap: Pliant Therapeutics Q1 Earnings
Via Benzinga
Pliant Therapeutics Reveals Encouraging Data From Liver Disease Trial
Pliant Therapeutics Inc (NASDAQ: PLRX) announced data from the INTEGRIS-PSC Phase 2a trial of bexotegrast in patients with primary sclerosing cholangitis (PSC) and suspected  
Via Benzinga
Why TD SYNNEX Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Soleno Therapeutics, Inc. (NASDAQ: SLNO) shares jumped 318.5% to $18.54 after the company released top-line results from randomized withdrawal period of study C602 of DCCR for Prader-Willi... 
Via Benzinga
Why Shares of Pliant Therapeutics Are Rising Tuesday
The company's lead therapy fared well in a phase 2a trial to treat two separate conditions. 
Via The Motley Fool
What 12 Analyst Ratings Have To Say About Pliant Therapeutics
Via Benzinga
Pliant Therapeutics Shares Fall After Long-Term Data Of Bexotegrast In Lung Fibrosis Study
Via Benzinga
Fisker, Intercept Pharmaceuticals, Immunovant And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones falling around 200 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Pre-market stock movers are among the biggest topics worth checking out on Tuesday and we have the latest news for investors! 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  Friday's session saw 169 companies set new 52-week lows. 
Via Benzinga
IPF Has A 0% Survival Rate Without Lung Transplant And A Median Survival Time Of 2-5 Years From Diagnosis – Could GRI-0621 Be The Solution?
Idiopathic Pulmonary Fibrosis (IPF) is a serious chronic lung disease characterized by the thickening and stiffening of the lung tissue surrounding the air sacs. The exact cause of IPF is unknown, but... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2023
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
First Republic Bank, Top Financial And Other Big Stocks Moving Lower On Monday
U.S. stocks traded lower, with the Nasdaq falling around 17 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
US Stocks Rise; Norwegian Cruise Line Posts Q1 Results
U.S. stocks traded higher this morning, ahead of the Federal Reserve’s monetary policy meeting. Following the market opening Monday, the Dow traded up 0.15% to 34,147.97, while the NASDAQ inched up... 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.